Mumbai: Global private equity fund Warburg Pincus is in advanced discussions to acquire Mumbai-based

孟买：全球私募股权基金华平投资正在就收购总部位于孟买的公司进行深入谈判。

Koye Pharma

科耶制药

, a drugmaker that has built its presence across women's health, respiratory care, and anti-diabetes drugs, besides consumer health and medical devices.

，这家制药商在女性健康、呼吸系统护理和抗糖尿病药物领域建立了自己的地位，此外还涉及消费者健康和医疗设备。

'The deal for Koye may be signed at roughly ₹300 crore,' a person aware of the development told ET.

“Koye的交易可能以大约3亿卢比的价格签署，”一位了解该发展的人士告诉《经济时报》。

Currently, Koye is owned by Aries Holdings, a healthcare-focused fund launched by Chinta Bhagat, the former Asia head of L Catterton.

目前，Koye由Aries Holdings持有，该公司是由曾任L Catterton亚洲区负责人的Chinta Bhagat创立的专注于医疗保健领域的基金。

Founded in 2013 by pharma marketing veterans Preetish Toraskar and Ravindra Shenoy, Koye Pharma was initially backed by Sequoia Capital (now Peak XV Partners). 'It has over 1250 medical representatives and after a prolonged phase of struggle is lately showing strong growth traction,' an industry executive told ET, adding Koye's sales is in the range of ₹160 crore, growing at par with the industry average of 10-11%.

Koye Pharma 由医药营销资深人士 Preetish Toraskar 和 Ravindra Shenoy 于2013年创立，最初得到了红杉资本（现为 Peak XV Partners）的支持。一位行业高管告诉《经济时报》，“该公司拥有超过1250名医药代表，在经历了一段长期的困境后，近期展现出强劲的增长势头。” 他还补充道，Koye 的销售额约为1.6亿卢比，增长速度与行业平均值10-11%持平。

.

。

For FY24-25, the company posted a revenue of ₹144 crore, according to Tracxn.

根据Tracxn的数据，该公司在2024-25财年实现了1.44亿卢比的收入。

Live Events

现场活动

For Warburg Pincus, Koye counts as the third company after

对于华平投资集团而言，高毅是继之后的第三家公司

Integrace Health

整合健康

and Maneesh Pharma for acquisitions as it attempts to string together a platform with a band of small and medium-sized companies for a play in the growing $25 billion market for medicines in India. Integrace Health is controlled by leading investors such as Temasek and True North. Warburg Pincus is in advanced discussions to acquire the non-TB formulations business of Mumbai-headquartered .

并且正在尝试通过整合一批中小型企业，为在印度不断增长的250亿美元医药市场中占据一席之地。Integrace Health由淡马锡和True North等领先投资者掌控。华平投资正在进行深入谈判，以收购总部位于孟买的非结核制剂业务。

Maneesh Pharmaceuticals

曼尼什制药公司

in a deal valued at around ₹1,600-1,800 crore, ET reported last week.

据《经济时报》上周报道，这笔交易的价值约为160亿至180亿卢比。

Aries Holdings spokesperson declined to comment while queries to Warburg went unanswered.

白羊座控股公司的发言人拒绝置评，而对沃伯格的询问则未获回应。

Industry experts noted the move is well-timed since mid-size companies are facing competitive heat from larger peers.

业内人士指出，这一举措时机恰当，因为中型公司正面临来自较大竞争对手的竞争压力。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)